Why the Luster of Gilead's Strong Q3 Results Isn't as Bright as It Seems
You'd think Gilead Sciences (NASDAQ: GILD) would be on top of the world right now. After all, the big biotech quickly emerged as a leader in treating COVID-19 and has announced sizable acquisitions to bolster its pipeline. Yet its shares are down year to date.
Gilead announced its third-quarter results after the market closed on Wednesday. Were those results enough to move the needle for the biotech stock? Probably not. Gilead posted strong Q3 results, but the glint isn't as bright as it might appear at first glance.
Image source: Getty Images.
Source Fool.com
